Cargando…

Kinetics of the B- and T-Cell Immune Responses After 6 Months From SARS-CoV-2 mRNA Vaccination in Patients With Rheumatoid Arthritis

OBJECTIVE: To assess the kinetics of the humoral and cell-mediated responses after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in rheumatoid arthritis (RA) patients treated with different immunosuppressive therapies. METHODS: Following vaccine completed schedule, health...

Descripción completa

Detalles Bibliográficos
Autores principales:	Farroni, Chiara, Picchianti-Diamanti, Andrea, Aiello, Alessandra, Nicastri, Emanuele, Laganà, Bruno, Agrati, Chiara, Castilletti, Concetta, Meschi, Silvia, Colavita, Francesca, Cuzzi, Gilda, Casetti, Rita, Grassi, Germana, Petrone, Linda, Vanini, Valentina, Salmi, Andrea, Repele, Federica, Altera, Anna Maria Gerarda, Maffongelli, Gaetano, Corpolongo, Angela, Salemi, Simonetta, Di Rosa, Roberta, Nalli, Gabriele, Sesti, Giorgio, Vaia, Francesco, Puro, Vincenzo, Goletti, Delia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8924958/ https://www.ncbi.nlm.nih.gov/pubmed/35309297 http://dx.doi.org/10.3389/fimmu.2022.846753

Ejemplares similares

ImmunosuppressiveTherapies Differently Modulate Humoral- and T-Cell-Specific Responses to COVID-19 mRNA Vaccine in Rheumatoid Arthritis Patients
por: Picchianti-Diamanti, Andrea, et al.
Publicado: (2021)

Booster dose of SARS-CoV-2 messenger RNA vaccines strengthens the specific immune response of patients with rheumatoid arthritis: A prospective multicenter longitudinal study
por: Farroni, Chiara, et al.
Publicado: (2022)

Humoral- and T-Cell–Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies
por: Tortorella, Carla, et al.
Publicado: (2022)

Longitudinal characterisation of B and T-cell immune responses after the booster dose of COVID-19 mRNA-vaccine in people with multiple sclerosis using different disease-modifying therapies
por: Aiello, Alessandra, et al.
Publicado: (2023)

Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine
por: Agrati, Chiara, et al.
Publicado: (2021)

Humoral and cellular responses to spike of δ SARS-CoV-2 variant in vaccinated patients with immune-mediated inflammatory diseases
por: Petrone, Linda, et al.
Publicado: (2022)

Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave
por: Aiello, Alessandra, et al.
Publicado: (2022)

Evaluation of the immunomodulatory effects of interleukin-10 on peripheral blood immune cells of COVID-19 patients: Implication for COVID-19 therapy
por: Najafi-Fard, Saeid, et al.
Publicado: (2022)

Prolonged and severe SARS-CoV-2 infection in patients under B-cell-depleting drug successfully treated: A tailored approach
por: D’Abramo, Alessandra, et al.
Publicado: (2021)

Older Age, a High Titre of Neutralising Antibodies and Therapy with Conventional DMARDs Are Associated with Protection from Breakthrough Infection in Rheumatoid Arthritis Patients after the Booster Dose of Anti-SARS-CoV-2 Vaccine
por: Picchianti-Diamanti, Andrea, et al.
Publicado: (2023)

In Acute Dengue Infection, High TIM-3 Expression May Contribute to the Impairment of IFNγ Production by Circulating Vδ2 T Cells
por: Cimini, Eleonora, et al.
Publicado: (2022)

Persistent Spike-specific T cell immunity despite antibody reduction after 3 months from SARS-CoV-2 BNT162b2-mRNA vaccine
por: Agrati, Chiara, et al.
Publicado: (2022)

Dynamic Evolution of Humoral and T-Cell Specific Immune Response to COVID-19 mRNA Vaccine in Patients with Multiple Sclerosis Followed until the Booster Dose
por: Ruggieri, Serena, et al.
Publicado: (2023)

Immunogenicity and safety of BNT162b2 COVID‐19 vaccine in a chronic lymphocytic leukaemia patient
por: Agrati, Chiara, et al.
Publicado: (2021)

Spike is the most recognized antigen in the whole-blood platform in both acute and convalescent COVID-19 patients
por: Aiello, Alessandra, et al.
Publicado: (2021)

Humoral and Cellular Response to Spike of Delta SARS-CoV-2 Variant in Vaccinated Patients With Multiple Sclerosis
por: Petrone, Linda, et al.
Publicado: (2022)

Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4(+) and CD8(+) T cell-SARS-CoV-2 response: comparison with a homemade interferon-γ release assay
por: Aiello, Alessandra, et al.
Publicado: (2022)

SARS-CoV-2 Breakthrough Infections According to the Immune Response Elicited after mRNA Third Dose Vaccination in COVID-19-Naïve Hospital Personnel
por: Santoro, Annapaola, et al.
Publicado: (2023)

Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Autoimmunity 1 Year Later: The Era of Vaccines
por: Picchianti Diamanti, Andrea, et al.
Publicado: (2021)

The first case of meningitis associated with SARS-CoV-2 BA.2 variant infection with persistent viremia
por: D'Abramo, Alessandra, et al.
Publicado: (2022)

Coinfection of tuberculosis and COVID-19 limits the ability to in vitro respond to SARS-CoV-2
por: Petrone, Linda, et al.
Publicado: (2021)

Impact of Prior Influenza and Pneumoccocal Vaccines on Humoral and Cellular Response to SARS-CoV-2 BNT162b2 Vaccination
por: Puro, Vincenzo, et al.
Publicado: (2021)

PMN-MDSC Frequency Discriminates Active Versus Latent Tuberculosis and Could Play a Role in Counteracting the Immune-Mediated Lung Damage in Active Disease
por: Grassi, Germana, et al.
Publicado: (2021)

VIDAS(®) TB-IGRA reagents induce a CD4+ and CD8+ T-cell IFN-γ response for both TB infection and active TB
por: Petruccioli, E., et al.
Publicado: (2022)

Vδ2 T-Cells Kill ZIKV-Infected Cells by NKG2D-Mediated Cytotoxicity
por: Cimini, Eleonora, et al.
Publicado: (2019)

Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway
por: D’Abramo, Alessandra, et al.
Publicado: (2022)

Mycobacterium tuberculosis Immune Response in Patients With Immune-Mediated Inflammatory Disease
por: Petruccioli, Elisa, et al.
Publicado: (2021)

Human Zika infection induces a reduction of IFN-γ producing CD4 T-cells and a parallel expansion of effector Vδ2 T-cells
por: Cimini, Eleonora, et al.
Publicado: (2017)

In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy
por: Petrone, Linda, et al.
Publicado: (2021)

The Third Dose of BNT162b2 COVID-19 Vaccine Does Not “Boost” Disease Flares and Adverse Events in Patients with Rheumatoid Arthritis
por: Picchianti Diamanti, Andrea, et al.
Publicado: (2023)

Cytokine Release Syndrome in COVID-19 Patients, A New Scenario for an Old Concern: The Fragile Balance between Infections and Autoimmunity
por: Picchianti Diamanti, Andrea, et al.
Publicado: (2020)

Myeloid-Derived Suppressor Cells Specifically Suppress IFN-γ Production and Antitumor Cytotoxic Activity of Vδ2 T Cells
por: Sacchi, Alessandra, et al.
Publicado: (2018)

A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients
por: Petrone, Linda, et al.
Publicado: (2021)

Direct and Indirect Impact of COVID-19 for Patients with Immune-Mediated Inflammatory Diseases: A Retrospective Cohort Study
por: Belleudi, Valeria, et al.
Publicado: (2021)

Immunological signature in human cases of monkeypox infection in 2022 outbreak: an observational study
por: Agrati, Chiara, et al.
Publicado: (2023)

A new procedure to analyze polymorphonuclear myeloid derived suppressor cells in cryopreserved samples cells by flow cytometry
por: Sacchi, Alessandra, et al.
Publicado: (2018)

Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection
por: Petruccioli, Elisa, et al.
Publicado: (2021)

SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus
por: Matusali, Giulia, et al.
Publicado: (2021)

Emulation of a Target Trial From Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients With COVID-19
por: Mazzotta, Valentina, et al.
Publicado: (2022)

In Vitro and In Vivo Crosstalk between Type I IFN and IL-8 Responses in SARS-CoV-2 Infection
por: Biava, Mirella, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0n57s0am47rrjsff968l4q30sn